Available at research and GMP grade to intensify production of recombinant AAV rAAV viral vectors at any scale from benchtop to 2000L scale bioreactor...

RNA/DNA in vivo delivery is the most powerful alternative to viral vectors for nucleic acid-based therapies. They offer substantial advantages in terms of reliability,safety and costs for nucleic-acid based therapies
Broad range of solutions is needed for manufacturing of functional proteins or antibodies at the desired scale in bacteria, yeast and mammalian cell expression systems
Optimised plasmid engineering and specific transfection reagents are key to enable protein expression in a wide range of adherent and suspension mammalian cell types